Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Status:
Completed
Trial end date:
2017-06-29
Target enrollment:
Participant gender:
Summary
This study will examine the effect intravenously administered rigosertib has on the
relationship between bone marrow blasts response and overall survival in myelodysplastic
syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after
treatment with azacitidine or decitabine.